- Fiscal 2026 net sales increased 17% to $1.52 billion, led by a 21% increase in the Animal Health segment.
- Net income rose to $99.7 million from $48.3 million, while adjusted net income increased 49% to $131.7 million.
- Adjusted EBITDA increased 39% to $255 million, and adjusted diluted EPS rose 48% to $3.22.
- Fourth-quarter sales increased 5% to $396.7 million, with adjusted EBITDA up 29% to $64.2 million.
- For fiscal 2027, Phibro projects sales of $1.55 billion to $1.60 billion and adjusted EBITDA of $258 million to $268 million.
- Phibro also plans to close its Chicago Heights, Illinois, manufacturing facility in summer 2027, affecting approximately 100 employees.
Phibro Animal Health Corporation reported higher sales and profitability for its fiscal year ended June 30, 2026, with growth in its Animal Health business helping push annual revenue above $1.5 billion.
Net sales reached $1.52 billion, up 17% from $1.30 billion in fiscal 2025. Net income increased to $99.7 million from $48.3 million, while diluted earnings per share increased to $2.43 from $1.19.
On an adjusted basis, EBITDA rose 39% to $255 million, adjusted net income increased 49% to $131.7 million and adjusted diluted EPS climbed 48% to $3.22.
Gross profit increased 28% to $512.5 million, while gross margin improved to 33.8% from 30.9% a year earlier.
Animal Health leads sales growth
Phibro’s Animal Health segment generated $1.16 billion in fiscal 2026 sales, an increase of 21%.
Sales of medicated feed additives and other products increased 25% to $810.7 million, including $146.1 million in incremental revenue from products in the MFA portfolio acquired in October 2024.
Nutritional specialty sales increased 9% to $195.1 million, driven by higher worldwide demand and increased companion animal sales. Vaccine sales rose 14% to $156.4 million, with the company citing growth in poultry products in Latin America as well as higher domestic and international demand.
Animal Health adjusted EBITDA increased 37% to $303.6 million.
Mineral Nutrition sales increased 11% to $282.3 million, while Performance Products revenue declined 8% to $73.5 million.
Fourth quarter maintains growth
For the fourth quarter, Phibro reported net sales of $396.7 million, a 5% increase from the same period last year.
Quarterly net income increased 26% to $21.7 million, and adjusted EBITDA rose 29% to $64.2 million. Adjusted net income increased 37% to $35 million, while adjusted diluted EPS increased 35% to $0.85.
The company attributed the improvement in quarterly gross profit partly to higher sales volume and a favorable product mix. Fourth-quarter gross margin increased to 33.9% from 29% in the prior-year period.
Phibro provides fiscal 2027 outlook
For the fiscal year ending June 30, 2027, Phibro expects net sales of $1.55 billion to $1.60 billion, representing approximately 4% growth at the midpoint of its guidance.
The company projects net income of $122 million to $132 million and adjusted EBITDA of $258 million to $268 million. Adjusted net income is expected to range from $140 million to $147 million, with adjusted diluted EPS of $3.41 to $3.59.
Phibro said its outlook assumes continued growth across Animal Health, Mineral Nutrition and Performance Products. The forecast assumes minimal sales of virginiamycin in Brazil because the company has not yet obtained required therapeutic indications there.
Chicago Heights manufacturing site to close
Phibro also announced plans to close its Chicago Heights, Illinois, manufacturing facility following a review of the production network it expanded through its 2024 MFA acquisition.
Production at the site is expected to end during summer 2027, affecting approximately 100 employees. Products manufactured there are expected to be transferred to other Phibro facilities and selected third-party contract manufacturers.
President and CEO Dani Bendheim described the closure as a strategic consolidation intended to align the company’s manufacturing footprint with future needs and improve efficiency.
The announcement also marks the formal conclusion of Phibro Forward, the company’s three-year transformation program. Phibro said initiatives developed through the program continue to contribute to its earnings performance.
Readers can review Phibro Animal Health’s full fiscal 2026 earnings report, financial tables, non-GAAP reconciliations and investor materials at Phibro’s Investor Relations site.
Information sourced from the company’s earnings release.
